Akebia Therapeutics to Present at Upcoming Investor Conference

CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 15, 2018– Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that its President and Chief Executive Officer, John P. Butler, will

Akebia Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 2, 2018– Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), granted five newly-hired employees options to purchase an aggregate of 10,450 shares

Akebia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Mar. 23, 2018– Akebia Therapeutics, Inc. (Nasdaq:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced the pricing of an underwritten public offering of 8,500,000 shares of